Detalles de la búsqueda
1.
Bevacizumab plus FOLFIRI after failure of platinum-etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial.
Lancet Oncol
; 24(3): 297-306, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36739879
2.
Avelumab vs Standard Second-Line Chemotherapy in Patients With Metastatic Colorectal Cancer and Microsatellite Instability: A Randomized Clinical Trial.
JAMA Oncol
; 9(10): 1356-1363, 2023 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37535388
3.
Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: The PRODIGE 41-BEVANEC randomized phase II study.
Dig Liver Dis
; 50(2): 195-198, 2018 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-29258812
Resultados
1 -
3
de 3
1
Próxima >
>>